GLYCAEMIC RESPONSE · HBA1C REDUCTION
1.2 – 1.6%
From 8.6% → predicted 7.0–7.4% at 6 months
72% of trial mean
Attenuated vs SUSTAIN-6 mean of 1.5% — TCF7L2 TT + KCNQ1 variant. Escalate to 1.0 mg target dose. Fundus review mandatory at Wk 12.
TWYN360
Digital twin simulation platform — clinical edition v2.1
Sample ID
OD10576
Sample ID
OD10576
Patient
Mr. Arjun R. Krishnamurthy
47 YRS · MALE · T2DM · NASH · CKD-G2
ABC HOSPITALS, HYDERABAD
Sim active
DR. PRIYA NAIR · DM ENDOCRINOLOGY
Simulation window — physiological digital twin
Semaglutide (Ozempic) 0.25 mg → 1.0 mg SC QW
BODY TEMP
37.1°C
BLOOD PRESSURE
142/88mmHg
PULSE RATE
78bpm
SpO₂
97%
eGFR
72mL/min
hsCRP
4.8mg/L
Loading twin model
LIVER RESPONSE
30-40% ↓Hepatic Fat
PANCREAS RESPONSE
PreservedBeta-cell
STOMACH RESPONSE
DelayedEmptying
KIDNEYS RESPONSE
25-35% ↓Renal ACR
HEART RESPONSE
~20% ↓MACE Risk
BRAIN RESPONSE
SuppressedAppetite
ECG — live rhythm
Parameter tuning
GLYCAEMIC PARAMETERS
HbA1c baseline
8.6%
Fasting glucose
168 mg
HOMA-IR
7.6
DOSING PARAMETERS
Sema dose (mg)
1.00mg
Weeks elapsed
W0
LIFESTYLE MODIFIERS
Exercise days/wk
0d
Sleep quality
4/10
Stress level
8/10
Dietary compliance
35.0%
Genetic risk flags
TCF7L2 TTKCNQ1 ▲ADRB3 Trp64ArgFTO AAGLP1R HetDPP4 Resistant
Comorbidity flags
NASHCKD G2MicroalbuminuriaHypertriglyc.HypertensionASCVD High Risk
Predicted treatment outcomes at 6 months
SPRA v1.4 · SUSTAIN-6 calibrated · South Indian phenotype
WEIGHT RESPONSE · BODY WEIGHT LOSS
3.5 – 5.0kg
3.7–5.3% body weight · est. baseline ~94 kg
58% of trial mean
Below trial mean (4–6 kg) — ADRB3 Trp64Arg + sedentary lifestyle. Structured exercise prescription is pharmacologically mandatory.
COMPOSITE SPRA SCORE
62/ 100
MODERATE-GOOD
Score >60 = therapy beneficial
Genetics 12/20 · PK 14/15 · PD 10/15 · Epigenetic 8/15 · Lifestyle 9/20 · Safety 9/15. All lifestyle domains are modifiable.
Full report sections — expand to view
Sections 01–12 · ABC Hospitals, Hyderabad · Confidential